What insurance policy changes affect HCPCS J3404?

There are 20 tracked policy changes affecting HCPCS J3404, including updates from Anthem BCBS, Health Net, Blue Cross Blue Shield of Rhode Island. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J3404?

Payers that have issued tracked updates for HCPCS J3404 include: Anthem BCBS, Health Net, Blue Cross Blue Shield of Rhode Island, BCBS Michigan, Texas Medicaid, Capital Blue Cross, Kansas Medicaid (KanCare), Michigan Medicaid - MDHHS, Blue Cross & Blue Shield of Mississippi.

How do I get notified when HCPCS J3404 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J3404. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J3404?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J3404 — Injection, zopapogene imadenovec-drba suspension, per therapeutic dose: Insurance Policy Changes

J3404 Insurance Policy Changes

HCPCS J3404 is officially defined as "Injection, zopapogene imadenovec-drba suspension, per therapeutic dose." HCPCS J3404 is referenced in 20 tracked payer policy changes from Anthem BCBS, Health Net, and 7 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3404 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

[Ohio] Specialty pharmacy updates for May 2026

Anthem BCBS·Effective Aug 1, 2026

Effective August 1, 2026, Anthem is implementing new prior authorization, quantity limit, step therapy, and site of care requirements for 16 specialty pharmacy medications across multiple clinical criteria documents. Billing teams must update systems to require prior authorization for these drugs and verify step therapy status (non-preferred medications require step therapy) before claims submission. Patients currently receiving these medications without authorization may be affected, requiring proactive outreach.

J3404 Insurance Policy Changes

[Virginia] Specialty pharmacy updates for May 2026

[Georgia] Specialty pharmacy updates for May 2026

[New York] Specialty pharmacy updates for May 2026

[Ohio] Specialty pharmacy updates for May 2026

26-629 Updates to Prior Authorization Requirements

26-630 Updates to Prior Authorization Requirements

Additional HCPCS Level II Code Changes and Modifier Changes

HCPCS 1st-quarter update: New, deleted codes

First Quarter 2026 HCPCS Updates for Texas Medicaid

First Quarter 2026 HCPCS Updates for the CSHCN Services Program

AB2026-05-002 Medicare only

Additional drugs to require prior authorization for Medicare Advantage members, starting May 11

KMAP BULLETIN: HCPCS Codes Update – April 2026

26-628 Updates to Prior Authorization Requirements

26-631 Updates to Prior Authorization Requirements

HCPCS replacement codes established, effective April 1, 2026

MMP 26-15: Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Code Updates

Prior Authorization Criteria for Zopapogene Imadenovec-drba (Papzimeos) Effective May 1, 2026

State and School Employees' Health Insurance Plan - Papzimeos (zopapogene imadenovec-drba)

Papzimeos (zopapogene imadenovec-drba)